Cogstate

Congratulations to the team at Tisento Therapeutics on publishing this important work – it was a privilege for Cogstate scientists to be involved! Your dedication to understanding the lived experience of those with MELAS is making an impact in the field and ensuring that clinical trials are designed with patients’ voices at the center. 

Caretakers are often unsung heroes. The countless hours driving to appointments, the long nights worrying about the future, and the days taken off work are all just the tip of the iceberg in the unending selfless service rendered in support of loved ones. Beyond the everyday activities, many caretakers also participate in clinical trials alongside their loved ones, offering insights that are vital in understanding the impact of treatments. Without question your contributions are improving outcomes for generations to come. From all of us at Cogstate, we thank you. #NFCMonth #CaregivingAroundTheClock #CaregivingHappens

Today, on Phelan-McDermid Syndrome (PMS) Awareness Day, let’s take a moment to recognize the strength and resilience of individuals and families affected by this rare neurodevelopmental disorder. At Cogstate, we’re grateful to be part of the broader community of researchers, clinicians and advocates working together to deepen our understanding and support research that brings us closer to meaningful progress for those living with PMS and other rare diseases.   #PMSAD #EveryStoryShinesGreen #phelanmcdermidsyndrome #RareDiseaseAwareness

91% of U.S. adults own a smartphone [1] which opens the door for research teams to deliver more accessible, accurate, and representative cognitive testing in clinical trials through unsupervised, remote administration utilizing personal devices. Svenja Wacker, PhD (Neuropsychology Science Director) presented data at the 2025 ISCTM Spring Conference showcasing the strengths of the Cogstate Brief Battery as a valid option for remote, self-administered cognitive testing via smartphone. Learn more about this research and explore the data here: https://buff.ly/juxSbOg [1] Pew Research, 2024

The Clinical Dementia Rating (CDR) scale remains a cornerstone in dementia research, valued for its use of informant interviews to provide rich, contextual insight into cognitive function. However, its ability to detect meaningful change depends on rater expertise, rigorous training, and careful protocol planning. Our latest blog explores practical strategies to increase signal detection and ensure reliable outcomes in your Alzheimer’s disease studies. Read the blog: https://buff.ly/EA3sO8u

For years, Cogstate team members have laced up their sneakers to support the Alzheimer's Association #Walk2EndAlz. Even now as a fully remote company, we make time to come together, especially for causes that matter. Last weekend, our #CogstateCrew in North Carolina walked in honor of loved ones, friends, and the millions impacted by this disease. 💜 As a small way of supporting, Cogstate matches every dollar team members raise. We are honored to be part of the fight to #EndAlz.

For decades, the ADAS-Cog has been considered a gold standard in Alzheimer’s disease clinical trials and is one of the most widely used tools in clinical research for assessing cognitive function in Alzheimer’s patients. However, this legacy tool has limitations when it comes to meeting the scale and complexity of modern clinical trials. Explore insights from Cogstate’s scientific leadership about the key advantages, unique challenges, and considerations of utilizing the ADAS-Cog. Read the blog here 👉: https://buff.ly/pFXYoEQ

In a recent pharmaphorum article, Cogstate Chief Medical Officer, Kaycee Sink, MD, MAS, joined Paul O'Donohoe, Senior Director, eCOA Product and Science at Medidata Solutions to share insights about the evolution of Alzheimer’s disease clinical trials. Together they discussed trial design elements that are important for sponsor teams, the growing role of technology and wearables in data collection, and how sites and participants are adapting to the shifting landscape.   Read the full article here: https://lnkd.in/eWt4erMx #Medidata #EndAlz #Alzheimersdisease

The Cogstate team was delighted to present CNS insights and connect with industry colleagues during the 5th Annual Nordic Innovation Day! Thanks to Lundbeck and Medidata Solutions for the invite to participate at this fantastic event.

What makes the ADAS-Cog effective? How can you appropriately leverage the MMSE? When is the CDR the preferred scale? The common and gold standard endpoints in Alzheimer’s disease (AD) have advantages and unique challenges that must be anticipated for trial success. It's crucial that research teams understand these nuances when considering how to approach endpoint selection, rater training, and data quality monitoring.  Based on decades of AD trial experience, Cogstate scientists have compiled rating scale insights to create the Alzheimer’s Disease Clinical Trial Endpoint Guide. Review the strengths, challenges and considerations around the most widely used scales in AD drug development here 👉: https://buff.ly/Uf2pfeb